Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Clinical trial results Company update Drug approval AI-generated analysis

πŸ“ˆ Moderna stock surged 658% year-to-date to $223.60 driven by positive late-stage trial results for its Intismeran cancer vaccine developed with Merck.

πŸ’Š The personalized cancer vaccine showed a 49% reduction in recurrence risk when paired with Keytruda, transforming the company's narrative from a COVID play to an oncology-focused story.

πŸ“‰ Moderna reported a significant loss of $782 million in Q2 on revenue of $145 million, indicating ongoing financial challenges despite the stock rally.

⚠️ The stock trades at 38.75 times trailing sales, significantly above the analyst consensus price target of $122.67 and a model fair value of $134.45.

πŸ”¬ Moderna has nine Phase 2/3 trials for Intismeran covering melanoma, lung, bladder, and kidney cancer, plus four approved products including Spikevax.

❌ The company's norovirus vaccine failed to meet statistical endpoints at a Phase 3 interim analysis, adding risk to its broader pipeline portfolio.

πŸ“… Third-quarter earnings are scheduled for November 6, with management expecting approximately 55% of second-half revenue to be recognized in Q3.

πŸš€ Management indicated that positive melanoma data could lead to an accelerated regulatory review for the Intismeran cancer vaccine.

πŸ₯ Moderna holds four approved products and aims to have six or seven drugs by 2028 according to industry panelists.

πŸ“‰ Shares remain 31% below their five-year high of $324.21, suggesting the current price may still be below historical peaks despite recent gains.

Bullish Signals
  • Moderna's personalized cancer vaccine, Intismeran, showed a 49% reduction in recurrence risk when combined with Keytruda in its first late-stage trial.
  • The company successfully transformed its market narrative from a post-COVID play to a promising oncology pipeline story following positive clinical data.
  • Investors anticipate Moderna could have six or seven drugs by 2028, indicating strong potential for future product diversification and revenue growth.
  • Positive melanoma data for Intismeran could trigger an accelerated regulatory review, potentially speeding up market entry for the cancer vaccine.
Risk Factors
  • Moderna lost $782 million in Q2 on revenue of $145 million, reflecting significant ongoing financial losses despite recent stock price gains.
  • The stock trades at a premium valuation of 38.75 times trailing sales, which is well above the analyst consensus target of $122.67 and model fair value of $134.45.
  • The company's norovirus vaccine failed to meet statistical endpoints at a Phase 3 interim analysis, highlighting risks within its broader pipeline.
  • Analyst consensus ratings are dominated by Hold and Sell recommendations due to the high current price relative to projected earnings declines.
Full Analysis
Moderna (MRNA) stock has surged 658% year-to-date, reaching a premarket price of $223.60 following positive late-stage trial data for its personalized cancer vaccine, Intismeran. Developed in partnership with Merck, the vaccine demonstrated a 49% reduction in recurrence risk when combined with Keytruda, successfully shifting investor sentiment from a post-COVID narrative to a robust oncology pipeline story. Despite the rally, the stock trades at a significant premium to Wall Street expectations, with an analyst consensus price target of $122.67 and a separate valuation model suggesting a fair value of $134.45. The company reported a substantial loss of $782 million in the second quarter on revenue of $145 million, highlighting that current share prices assume future regulatory approvals and commercial success that have not yet been realized. Investors face key upcoming catalysts including third-quarter earnings scheduled for November 6, which management expects to capture about 55% of second-half revenue. The company also faces specific pipeline risks, such as the recent failure of its norovirus vaccine in a Phase 3 interim analysis, while awaiting potential accelerated regulatory reviews for Intismeran if melanoma data remains positive. Analysts maintain a mix of Hold and Sell ratings due to the high valuation multiple of 38.75x trailing sales and the gap between current pricing and projected earnings declines. While the oncology pipeline includes nine Phase 2/3 trials covering various cancers, the stock's performance now hinges on delivering on future commercial milestones rather than past pandemic-related revenue.